Leucine in Obesity: Therapeutic Prospects

详细信息    查看全文

• 作者：Kang Yao¹ ; ² ; ⁹ ; Yehui Duan¹ ; ⁴ ; ⁹ ; Fengna Li¹ ; ⁵ ; ^{lifengna@isa.ac.cn" class="auth_mail" title="E-mail the corresponding author} ; Bie Tan¹ ; ⁵ ; Yongqing Hou⁶ ; Guoyao Wu¹ ; ⁶ ; ⁷ ; Yulong Yin¹ ; ² ; ³ ; ⁸ ; ^{yinyulong@isa.ac.cn" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Trends in Pharmacological Sciences
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：37
• 期：8
• 页码：714-727
• 全文大小：2125 K

文摘

Obesity develops from an imbalance of energy homeostasis and is associated with chronic low-grade inflammation in white adipose tissues (WAT). Inflammation is involved in the pathophysiology of many obesity-induced disorders including insulin resistance and diabetes. Increasing evidence has shown that dietary leucine supplementation positively affects the parameters associated with obesity and obesity-related metabolic disorders. The beneficial effects include increased loss of body weight, reduced WAT inflammation, improved lipid and glucose metabolism, enhanced mitochondrial function, and preserved lean body mass. Although these beneficial effects have not been clearly established, dietary leucine supplementation, either alone or as part of a therapeutic regimen, may be a good nutritional tool in the prevention and management of obesity and obesity-induced metabolic disorders.